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a b s t r a c t
Introduction: New 188Re and 99mTc peptide conjugates with substance- P (SP) were prepared and
biologically evaluated. The radiopharmaceuticals have been labelled with the [M"N]2þ (M¼99mTc,
188Re) core using a combination of pi-donor tridentate and pi-acceptor monodentate ancillary ligands.
Methods: The new radiopharmaceuticals have been prepared through a two-step reaction by simulta-
neous addition of the tridentate and monodentate ligands to a vial containing a preformed [M"N]2þ
core. The tridentate ligand was formed by linking two cysteine residues to the terminal arginine of the
undecapeptide SP, whereas the monodentate ligand was a tertiary phosphine. The preparation of
the corresponding Re-188 derivative required developing a more complex chemical procedure to obtain
the [Re"N]2þ core in satisfactory yields. Characterization of the resulting products was obtained by
chromatographic methods. Biological evaluation was performed for both Tc-99m and Re-188 derivatives
by in-vitro studies on isolated cells expressing NK1-receptors. In-vivo imaging in mice was carried out
using a small-animal YAP(S)PET tomograph.
Conclusion: New Tc-99m and Re-188 peptide radiopharmaceuticals with SP have been prepared in high-
yield and with high-speciﬁc activity. Both Tc-99m and Re-188 peptide radioconjugates exhibit high
afﬁnity for NK1 receptors, thus giving further evidence to the empirical rule that structurally related
Tc-99m and Re-188 radiopharmaceuticals exhibit identical biological properties.
& 2014 Elsevier Ltd. All rights reserved.
1. Introduction
Technetium-99m is still the most widely used diagnostic radio-
nuclide owing to its almost ideal nuclear properties (Eγ¼140 keV,
t1/2¼6.06 h) and easy availability through the transportable
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Mo-99/Tc-99m generator. Similarly, rhenium-188 was early recog-
nized as one of the most attractive radionuclide for therapy as it
decays through the emission of a high-energy β-particle
(Eβmax¼2.1 MeV, t1/2¼16.9 h) with an associated γ-emission
(155 keV) that can be conveniently utilized for imaging purposes
(Ferro-Flores and Arteaga de Murphy, 2008). This radionuclide is
also produced, in very high speciﬁc activity and radionuclidic
purity, through the transportable 188W/188Re generator system
(Pillai et al., 2012). These two transition elements share a similar
chemistry, which allows obtaining analogous complexes having
the same structural characteristics with many categories of ligands
though this does not occur ubiquitously for all types of compounds
(Bhattacharyya and Dixit, 2011). However, a key result that has
been ﬁrmly demonstrated experimentally maintains that, when a
pair of 99mTc and 188Re complexes exhibit exactly the same
molecular structure and chemical composition, but differ only
for the metal ion, they exhibit the same biodistribution properties
(Duatti, 2011). Thus, these two structurally identical complexes
constitutes a true theranostic (diagnosticþtherapeutic) pair and
not simply a surrogate pair like 111In/90Y and 68Ga/177Lu] com-
plexes (Kelkar and Reineke, 2011; Price and Orvig, 2014). This
result can be conveniently exploited to facilitate the development
of structurally identical 188Re therapeutic agents through the
preliminary investigation of the pharmacokinetic and pharmaco-
dynamics properties of the corresponding 99mTc complexes (Park
and Kim, 2013).
Recently, we described a new chelating arrangement for
developing theranostic pairs of 99mTc and 188Re radiopharmaceu-
ticals. This molecular fragment is composed by a combination of
tridentate and monodentate ligands bound to a [M"N]2þ
(M¼99mTc, 188Re) group as schematically pictured in Fig. 1
(Boschi et al., 2013). The [M"N]2þ (M¼99mTc, 188Re) inorganic
functional group exhibits an elegant and predictable chemistry
sharply controlled by the chemical nature of the coordinating
ligands. In this speciﬁc example, the tridentate ligand binds the
metallic fragment through a set of three pi-donor atoms whereas
the monodentate ligand through a single pi-acceptor atom (Boschi
et al., 2012). The resulting mixed complexes form exclusively when
these two type of ligands are simultaneously added to the
intermediate [M"N]2þ fragment, thus indicating that this mole-
cular arrangement are endowed with high structural stability.
A signiﬁcant advantage of this approach is that suitable tridentate
chelating systems can be conveniently formed by joining pair of
aminoacids or pseudo-aminoacids such as, for example, cysteine–
cysteine, cysteine–isocysteine or cysteine–mercaptoacetic acid
(Boschi et al., 2013). This result may provide an almost ‘natural’
and straightforward method for labeling peptides with Tc-99m
and Re-188 since it only requires lengthening the original peptidic
sequence with a pair of these chelating aminoacids.
The present work was mostly devoted to investigate the
application of the new labeling approach with Tc-99m and Re-
188 to a model peptide. The undecapeptide substance-P (SP) was
selected for this purpose. SP is the most important member of the
tachykinin family that constitutes the major endogenous ligand for
the NK1 receptor type. Tachykinins are excitatory neuropeptides
synthesised in neuronal and glial cells of the human central and
peripheral nervous system. These peptides act as excitatory
neurotransmitters and/or neuromodulators and induce DNA
synthesis leading to stimulation of cell division and proliferation.
Their biological responses are triggered via the well-established
tachykinin receptors NK1, NK2 and NK3 that belong to the G
protein-coupled receptor family (GPCRs). It has been well estab-
lished that SP plays an important role in modulating pain
transmission and may be also involved in the pathogenesis of
inﬂammatory diseases (Van Hagen et al., 2005). The presence of
functional NK1 receptors has been documented in malignant brain
tumors of glial origin, medullary thyroid cancer, non-small cell
lung cancer and pancreatic carcinoma. It has been suggested that
targeting speciﬁc SP-NK1 receptors might provide a potential
strategy for developing both new tumor-speciﬁc diagnostic agents
and radionuclide-based anti-cancer therapy (Ansquer et al., 2009).
In the following, the preparation and characterization of novel
Tc-99m and Re-188 radiopharmaceuticals containing a ‘naturally’
modiﬁed SP peptide sequence are described. A preliminary biolo-
gical evaluation of the resulting radiolabeled conjugates is also
reported.
2. Materials and methods
2.1. General
Unless stated otherwise, chemicals were obtained from com-
mercial sources and used without further puriﬁcation. Protected
amino acids, resins and reagents for the solid phase peptide
synthesis were purchased form Novabiochem (Laufelﬁngen, Swit-
zerland) or Anaspec (Campus Drive, Fremont, CA, USA).
Succinic dihydrazide [SDH¼H2N–NH–(O¼)C–(CH2)2–C(¼O)–NH–
NH2], γ-hydroxypropylcyclodextrin, 1,2-diaminopropane-N,N,N0N0-tet-
raacetic acid, sodium dihydrogen phosphate monohydrate (NaH2-
PO4 %H2O), disodium hydrogen phosphate heptahydrate (Na2HPO4 %
7H2O) the sodium salt of oxalic acid (Na2C2O4), SnCl2 %2H2O, ascorbic
acid, tris(2-cyanoethyl)phosphine [PCN¼P(CH2CH2CN)3], triﬂuoroace-
tic acid (TFA), L-cysteine and glutathione (GSH) were obtained from
Aldrich. Polyethyleneglycol-600 diacid (HO2C-PEG600-CO2H) was pur-
chased from Sigma-Aldrich. The compound methyl 2-(3,4-dichloro-
benzoyl)-1-methylhydrazinecarbodithioate [Cl2C6H3C(¼O)NH–N(CH3)
SCH3¼MDTCZ] and butyl 2-(3,4-dichlorobenzoyl)-1-methylhydrazi-
necarbodithioate [Cl2C6H3C(¼O)NH–N(CH3)SC4H9¼BDTCZ], were
prepared according to literature procedures (Szczesio et al., 2012).
Rhenium-188, as carrier free [188ReO4]Na in physiological solution,
was obtained by elution from a 188W/188Re generator provided by
Polatom (Poland). To obtain high volumic activity, the generator was
equipped with a concentration system assembled as described else-
where (Guhlke et al., 2000). Technetium-99m, as [99mTcO4]Na in
physiological solution, was obtained from a 99mMo/99mTc generator
Elumatics III (CisBio/IBA Molecular, France).
2.2. Peptide synthesis and puriﬁcation
The aminoacidic sequence of the undecapeptide substance-P was
prolonged by addition of two sequential cysteine residues to
N-terminal to afford the bifunctional ligand Cys-Cys-Arg-Pro-Lys-
Pro-Gln-Gln-Phe-Phe-Gly-Leu-Met-NH2 (Cys-Cys-SP). In Figs. 1 and
2, drawings of the chemical structures of SP and Cys-Cys-SP areFig. 1. Drawing of the chemical structure of substance-P (SP).
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reported, respectively. Peptides were synthesized with an automatic
solid phase peptide synthesizer Syro II (Biotage, Uppsala, Sweden)
using Fmoc/tBu chemistry (Benoiton, 2005). The resin 4-(20,40-
dimethoxyphenyl-Fmoc-aminomethyl)-phenoxyacetamido-norleu-
cyl-MBHA (Rink amide MBHA resin) was used as a solid support. The
resin was treated with 40% piperine/N,N-dimethylformamide (DMF)
and linked with Fmoc-Met-OH by using O-(7-azabenzotriazol-1-yl)-
1,1,3,3-tetramethyluronium hexaﬂuorophosphate (HATU) as coupling
reagent. For the synthesis of Cys-Cys-SP, the following N&-Fmoc
amino acids were sequentially coupled to the growing peptide chain:
Fmoc-Leu-OH, Fmoc-Gly-OH, Fmoc-Phe-OH, Fmoc-Phe-OH, Fmoc-Gln
(Trt)-OH, Fmoc-Gln(Trt)-OH, Fmoc-Pro-OH, Fmoc-Lys(Boc)-OH, Fmoc-
Pro-OH, Fmoc-Arg(Pmc)-OH, Fmoc-Cys(Trt)-OH and Fmoc-Cys(Trt)-
OH. All the Fmoc amino acids (4 equiv) were coupled to the growing
peptide chain by using HATU (4 equiv) in DMF in the presence of an
equimolar concentration of 4-methylmorpholine (NMM), and the
coupling reaction was carried out for 1 h. To improve the analytical
proﬁle of the crude peptide, capping with acetic anhydride (0.5 M in
DMF) in the presence of NMM (0.25 M in DMF) (3:1, v/v; 2 mL/0.2 g of
resin) was performed at any step with the only exception of the last
coupling. The mixture 40% piperidine/DMF was used to remove the
Fmoc group at every step. The peptide resin was washed with
methanol and dried in vacuo to yield the protected SP-Resin deriva-
tives. The protected peptide-resin was treated with reagent B (Solé
and Barany, 1992) (triﬂuoroacetic acid (TFA)/H2O/phenol/triisopropyl-
silane (88:5:5:2 v/v; 10 mL/0.2 g of resin) for 1.5 h at room tempera-
ture. After ﬁltration of the resin, the solvent was concentrated in
vacuo and the residue triturated with ether. The crude peptide was
puriﬁed by preparative reverse phase HPLC to yield a white powder
after lyophilisation.
Crude peptides were puriﬁed by preparative reversed-phase
HPLC using a Water Delta Prep 3000 system with a Jupiter column
C18 (250'30 mm, 300 A, 15 µm spherical particle size). The
column was perfused at a ﬂow rate of 20 mL/min with a mobile
phase containing solvent A (5%, v/v, acetonitrile in 0.1% TFA), and a
linear gradient from 0 to 70% of solvent B (60%, v/v, acetonitrile in
0.1% TFA) over 25 min for the elution of peptides. Analytical HPLC
analyses were performed on a Beckman 116 liquid chromatograph
equipped with a Beckman 166 diode array detector. Analytical
purity of the peptides were determined using a Luna C18 column
(4.6'100 mm, 3 µm particle size) with the above solvent system
(solvents A and B) programmed at a ﬂow rate of 0.5 mL/min using
a linear gradient from 0% to 80% B over 25 min. Purity of the ﬁnal
peptide was Z95% when monitored at 220 nm.
2.3. Preparation of Tc-99m and Re-188 peptide radioconjugates
Freshly generator-eluted Na[99mTcO4] (0.9 mL, (500 MBq) was
added to a nitrogen-purged vial containing 1.0 mg of solid SDH,
0.10 mg of SnCl2 and 0.10 mL of saline. The mixture was gently
swirled to ensure dissolution of the reagents and kept at room
temperature for 15 min to yield the [99mTc"N]2þ group. A
solution of Cys-Cys-SP, obtained by dissolving an amount of the
peptide ligand (in the range 0.5–0.05 mg) in 0.5 mL of saline, and
another solution, obtained by dissolving 0. 5 mg of PCN and 2.0 mg
of γ-hydroxypropylcyclodextrin in 0.5 mL of saline, were freshly
prepared and then simultaneously added to the reaction vial
containing the radioactive Tc-99m nitrido intermediate. The vial
was heated at 100 1C for 30 min. The radiochemical yield, as
determined by HPLC chromatography (see below), ranged from
92 to 96% by increasing the concentration of the peptide ligand
from 50 to 500 μg.
Glacial acetic acid (0.1 mL) was added to a vial containing
1.0 mg of SnCl2 %2H2O, 28.0 mg of sodium oxalate, 1.5 mg of
MDTCZ (or alternatively, BDTCZ) followed by freshly generator-
eluted Na[188ReO4] (1.5 mL, (300 MBq). The mixture was gently
warmed up to 50 1C to ensure dissolution of the reagents and then
kept at room temperature for 30 min. To the resulting solution,
Cys-Cys-SP (0.5&0.05 mg dissolved in 0.5 mL of saline) and 0.
5 mg of PCN (dissolved in 0.5 mL of saline containing 2.0 mg of γ-
hydroxypropylcyclodextrin) were simultaneously added. The mix-
ture was heated at 100 1C for 1 h. The radiochemical yield, as
determined by HPLC chromatography, ranged from 86 to 92% by
increasing the concentration of the peptide ligand from 50 to
500 μg.
2.4. Chromatography
Reversed-phase high performance liquid chromatography (RP-
HPLC) was employed to determine radiochemical yields of radiola-
belled compounds using a Beckman System Gold instrument
equipped with a programmable solvent model 126, a sample injection
valve 210A, a scanning detector Module 166, and a radioisotope
detector Model 170. Analyses were carried out using a reversed-
phase Agilent precolumn Zorbax 300SB-C18 (4.6'12.5 mm) and a
reversed-phase Agilent column Zorbax 300SB-C18 (4.6'250mm) at
the ﬂow rate of 1.0 mL/min. Elution was performed using a combina-
tion of solvent A (0.1% TFA inwater) and solvent B (0.1% TFA in CH3CN)
as mobile phase and the following gradient: 0&30min, %B¼0&100;
30&32min, %B¼100; 32&34min, %B¼100&0. Two main HPLC
peaks were observed for both Tc-99m and Re-188 peptide conjugates
corresponding to the formation of a syn/anti isomeric pair (see below).
Radiochemical yield for all products was expressed as the sum of the %
of peak areas (a and b) for the two isomers. Retention times (min)
were RTc¼15.2(a), 15.8(b) and RRe¼15.9(a), 16.5(b) for Tc-99m and Re-
188 radioconjugates, respectively.
For in vitro and in vivo studies, the radiocompounds were further
puriﬁed using the following procedure. The reaction mixture was
diluted with 8.0 mL of water and loaded onto a C18 Sep-Pak cartridge
(Waters, Milford, MA) previously activated with ethanol (95%, 5.0 mL)
and water (5.0 mL). The cartridgewas rinsed with water (20.0 mL) and
ethanol (60%, 3.0 mL). Finally, the radiocompound was recovered by
repeated elution with ethanol (0.4 mL followed by 3'1.0 mL). The
ﬁrst fraction was not utilized for biological studies. The remaining
fractions were combined, and ﬁnal radiochemical purity (RCP)
checked by HPLC (approximately, 100%). After slow evaporation of
the solvent by ﬂushing a nitrogen stream, isotonic saline was then
added to redissolve the radioconjugate.
2.5. Stability
The in vitro stability of 188Re and 99mTc complexes was
evaluated by monitoring radiochemical purity (RCP) at different
time points (15, 30, 60, 120 min for 99mTc complexes and 1, 3, 24 h
for 188Re complexes). After preparation, the selected radioactive
Fig. 2. Drawing of the chemical structure of Cys-Cys-substance-P (Cys-Cys-SP).
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compound was puriﬁed as described in the previous paragraph.
Then, 100 mL of the resulting eluate were incubated at 37 1C with
900 mL of saline or PBS. Experiments were conducted in triplicate.
Radiochemical purity (RCP) was measured by HPLC chromatogra-
phy. No signiﬁcant variation of RCP was observed for both Tc-99m
and Re-188 radioconjugates.
2.6. Cysteine and glutathione (GSH) challenge
PBS (250 mL, 0.2 mol/dm3, pH¼7.4), water (150 mL), a freshly
prepared aqueous solution of L-cysteine or GSH (10.0 mmol/dm3,
50 mL), and a volume of the appropriate HPLC-puriﬁed complex
(100 mL) were placed in a test tube and incubated in a water bath
in triplicate at 37 1C. A blank experiment was carried out using an
equal volume of saline. Experiments were conducted in triplicate.
Aliquots of the resulting solutions were withdrawn at 15, 30, 60,
120, and 360 min, and analyzed by HPLC. Both Tc-99m and Re-188
radioconjugates were found to be inert towards transchelation by
cysteine and GSH.
2.7. Stability in mouse, rat and human serum
Stability of Tc-99m and Re-188 radioconjugates was assessed in
mouse, rat and human serum using the following procedure. Freshly
prepared serum (225.0 μL) and the appropriate C18 Sep-Pak puriﬁed
radioconjugate (25.0 μL) were placed in a polypropylene tube and
incubated in a water bath, in triplicate at 37 1C. Aliquots of the
resulting solutions were withdrawn at 15, 30, 60 and 120min after
incubation, and analysed by HPLC chromatography.
3. Biological studies
3.1. In-vitro cellular studies
Cellular experiments with SP derivatives have been conducted
following methods described previously (Rangger et al., 2013).
U-87MG cells (CLS Cell Lines Service, Eppelheim, Germany) were
removed from the original medium using a procedure suggested
by the supplier and subcultured in Erlenmeyer tissue culture ﬂasks
(Dispomeyer, VWR International PBI, Milan, Italy) using Dulbecco’s
modiﬁed Eagle medium (DMEM) supplemented with 10% volume/
volume (v/v) heat-inactivated fetal bovine serum, 1% v/v penicillin/
streptomycin/L-glutamine solution, 1% v/v sodium pyruvate solu-
tion, and 1% v/v non-essential amino acid solution (NEAA). Cell
lines were grown to conﬂuence at 37 1C in a humidiﬁed atmo-
sphere of 95% air/5% carbon dioxide and split every 48 h. Similarly,
mouse ﬁbroblast cells (L-929) (CLS Cell Lines Service, Eppelheim,
Germany) were removed from the original medium and subcul-
tured in DMEM supplemented with 10% v/v heat-inactivated fetal
bovine serum, 1% v/v L-glutamine, 1% v/v NEAA, and 1% v/v
antibiotic/antimycotic in tissue culture ﬂasks. The cells were
grown to conﬂuence at 37 1C in a humidiﬁed atmosphere of 95%
air/5% carbon dioxide.
For experimental studies, the cancer cell line (U-87MG) and the
mouse ﬁbroblast cell line (L-929) as negative control were grown
overnight in a plastic sterile test-tube (Coltube, VWR International
PBI, Milan, Italy) until reaching a growth density of about 40–50%.
The radioconjugate, puriﬁed through a C18-Sep-Pak cartridge, was
diluted 1:250 times (approximately, 2'105 cpm) using the appro-
priate cell culture medium and incubated with cells for 15 min at
37 1C. After incubation, the test tube was centrifuged (3 min,
500g), supernatant was removed and cells were washed twice
with phosphate-buffered saline and counted using a gamma
counter (Minaxi 5550, Packard). Experiments were conducted in
triplicate. Cell uptake was calculated with respect to an aliquot of
the initial activity representing total activity. Uptake values
expressed as % of the total activity were 58.4970.35 (Tc-99m)
and 61.3771.02 (Re-188) for U-87MG cells and 2.9571.17 (Tc-
99m) and 1.9670.95 (Re-188) for L-929 cells.
3.2. Micro-SPECT/CT imaging studies
Animal experiments were carried out incompliance with the
relevant national laws relating to the conduct of animal experimenta-
tion and EU Directive 2010/63/EU. SPECT studies have been performed
using a YAP(S)PET scanner (Del Guerra et al., 2006). A mouse ((25 g)
was anesthetized with an intramuscular injection of a mixture of
ketamine (80 mg/kg) and xilazine (19 mg/kg) and then injected with
75MBq (2 mCi) of the 99mTc-labeled peptide to determine its whole-
body distribution. The mouse was scanned the ﬁrst time for 60 min
starting 20 min after injection. The SPECT acquisition consisted of
3 bed positions 3 cm apart, 20 min for each position, 128 views over
3601. The used energy window is 140&250 keV and the images were
reconstructed by using the iterative EM-ML algorithm including the
collimator response.
Radiographic images have been acquired using the digital
X-ray imaging system integrated into the YAP(S)PET scanner (Di
Domenico et al., 2007). Acquisition parameters for X-ray projec-
tions were: X-ray tube voltage¼35 kV, anode current¼1 mA,
exposure¼1 s, 8 views over 3601, magniﬁcation factor¼1.2. Sub-
traction of dark noise contribution and ﬂat ﬁeld corrections were
accomplished to obtain ﬁnal images.
Planar images were also collected in a second mouse, pre-
treated as described above after 180 min from injection of 92 MBq
(2.5 mCi), using the same scanner (image not reported here). At
the conclusion of the image acquisition, both animals were
sacriﬁced by cervical dislocation and thymus glands were excised,
washed with saline, weighed and counted for radioactivity.
Observed values were 0.0132 and 0.00938 expressed as percent
of injected activity per gram (%IA g&1), respectively.
4. Results and discussion
4.1. Preparation of peptide radioconjugates
Radiolabelling of the peptide Cys-Cys-SP with Tc-99m was
carried out through a well-established two-step method involving
the ﬁrst formation of the [99mTc"N]2þ core followed by addition
of the relevant coordinating ligands. The [99mTc"N]2þ group was
prepared by the usual reaction of [99mTc][TcO4]& with a reagent
capable to donate nitrido nitrogen atoms (N&3) in the presence of
a reducing agent. Succinic dihydrazide (SDH) and SnCl2 are
standard reagents commonly employed for this purpose (Boschi
et al., 2005). Simultaneous addition of both Cys-Cys-SP and tris
(2-cyanoethyl)phosphine (PCN) to the preformed [99mTc"N]2þ
group afforded the ﬁnal radioconjugate [99mTc][Tc(N)(Cys-Cys-SP)
(PCN)]. This compound is neutral as a result of the coordination of
the two terminal cysteine residues as a dianionic, tridentate
chelating system through two deprotonated thiol sulfur atoms
and one neutral, protonated, amino nitrogen atom. Residual
protonation of this nitrogen atom is responsible of the existence
of two isomeric forms of the resulting radioconjugate, which
originate from the reciprocal syn or anti (across or opposite)
position of the amino hydrogen with respect to the Tc"N triple
bond (Boschi et al., 2012). Despite this tiny structural difference,
the two isomers were well separated by HPLC as evidenced by the
presence of two adjacent peaks in the chromatographic proﬁle of
the ﬁnal Tc-99m compound (Fig. 3).
The preparation of the corresponding Re-188 analogue was
more demanding as expected from the differences in redox
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potentials between technetium and rhenium. In particular, the
reduction of [188Re][188ReO4]& needed an additional boost that
was imparted by the combined action of SnCl2 and oxalate ions
(Bolzati et al., 2000). A crucial role was played by the donor of N&3
ions, which has to be carefully selected since SDH was found not
to be a suitable reagent for producing the [188Re"N]2þ core. It
turned out that N-methyl S-methyl dithiocarbazate [DTCZ
¼H2NNC(¼S)SCH3], a compound previously employed as nitrido
donor reagent, was more effective in generating the [188Re"N]2þ
group (Boschi et al., 2003). However, DTCZ is also a good
coordinating ligand for the same group and this thereby carries
out the need for using a large excess of the ﬁnal ligands for its
removal. Evidently, this may constitute a drawback for peptide
labeling since usually the concentration of free peptide ligand
should be kept as lower as possible to avoid saturation of the
target biological receptors. Recently, we demonstrated that by
appending sterically encumbering chemical groups to the basic
DTCZ moiety signiﬁcantly impaired its coordination ability while
keeping unaltered its donor properties. For this purpose, the
derivative PEG-DTCZ was synthesized where a long polyethylene-
glycol chain was tethered to the terminal nitrogen atom of DTCZ
(Boschi et al., 2010). Though this reagent was highly efﬁcient in
affording the [188Re"N]2þ core, its preparation is lengthy and
cumbersome since it involves many puriﬁcation steps to achieve
the required purity. In this study, we employed the compounds
methyl 2-(3,4-dichlorobenzoyl)-1-methylhydrazinecarbodithioate
[Cl2C6H3C(¼O)NH–N(CH3)SCH3¼BDTCZ], or alternatively butyl 2-
(3,4-dichlorobenzoyl)-1-methylhydrazinecarbodithioate [Cl2C6H3C
(¼O)NH–N(CH3)SC4H9¼BDTCZ], as simpler derivatives of DTCZ,
which proved useful for obtaining the same result. The chemical
structures of these products are illustrated in Fig. 4. Using these
reagents, satisfactory yields of production of the ﬁnal [188Re][Re
(Cys-Cys-SP)(PCN)] conjugate were obtained. HPLC characteriza-
tion revealed the same chromatographic pattern corresponding to
the presence of syn and anti isomers, thus convincingly supporting
the conclusion that the Tc-99m and Re-188 derivatives share a
common structural arrangement.
A schematic illustration of the chemical structure of these
radiocompounds is reported in Fig. 5.
4.2. Stability
Both Tc-99m and Re-188 SP radioconjugates were found to be
stable in solutions and in mouse blood serum. However, incuba-
tion with rat and human serum showed marked species depen-
dence since a progressive decrease in RCP was measured over time
(Fig. 6). Speciﬁcally, in rat serum a sharp decrease of RCP below
80% was observed after 30 min, whereas the same decomposition
was detected in human serum after 60 min. At present, it remains
unclear whether this in vivo instability resulted from decomposi-
tion affecting the metal containing moiety, from oxidation of the
methionine residue on the peptide sequence (Bjellaas et al., 2004;
Guan et al., 2003) or other degradation processes. The remarkable
Fig. 3. Representative HPLC chromatogram of the compound [99mTc][Tc(N)(Cys-Cys-SP)(PCN)].
Fig. 4. Drawings of the chemical structures of MDTCZ and BDTCZ.
Fig. 5. Drawings of the chemical structures of [M(N)(Cys-Cys-SP)(PCN)] (M¼Tc-
99m, Re-188).
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differences between results obtained in mouse, rat and human
serum point to some speciﬁc species dependent mechanism for
the observed instability rather than to unspeciﬁc oxidative decom-
position. Besides, the absence of detectable amounts of free
pertechnetate and perrhenate supports the view that the chelating
system retains its integrity in the biological medium without
release of the radiometal. This relative inertness of the metallic
moiety has been also evidenced in challenging experiments with
cysteine and glutathione. However, further comparative studies
are required to clarify the origin of the observed instability, as
particularly found in rat serum.
4.3. Biological characterization
Though the present work was mostly devoted to investigate the
application of a new labeling method to SP as a model peptide,
preliminary characterization of the afﬁnity of the resulting radio-
conjugates for NK1 receptor expressing cells have been carried
out. Incubation with either Tc-99m or Re-188 SP radioconjugates
resulted in no detectable binding with the negative control cell
line L-929. The most pronounced cell surface binding was
observed after incubation with U-87 MG cells, which reﬂects the
expression level of NK1 receptors on these cells. Retention of
radioactivity was signiﬁcant with both Tc-99m and Re-188 radio-
conjugates, thus suggesting a comparable afﬁnity for the same
surface membrane receptors.
Whole-body biodistribution studies were carried out with a
hybrid SPECT/CT YAP(S)PET small-animal tomograph after admin-
istration of the Tc-99m analogue. Images collected at 60 min post
injection showed a predominant kidney elimination and uptake in
a small region apparently associated with the thymus (Fig. 7)
where speciﬁc SP binding sites have been previously recognized
(Breeman et al., 1996; Van Hagen et al., 2005). This ﬁnding was
convincingly supported by ex-vivo measurement, which revealed
detectable radioactive accumulation in the thymus gland isolated
from the same animal employed for imaging studies. Similarly,
planar images collected at 180 min after administration of the
tracer were consistent with this result as they showed uptake in a
large region including the thymus, heart and some delayed liver
and intestinal washout. Signiﬁcant uptake in salivary glands was
also observed. Ex-vivo measurements ruled out myocardial accu-
mulation and conﬁrmed uptake by the thymus. In the present
work, no further investigation was pursued to determine whether
the observed uptake was receptor-mediated or simply unspeciﬁc
and, thus, more accurate studies are required.
5. Conclusions
New Tc-99m and Re-188 radioconjugates of SP have been
successfully prepared by applying a novel labeling strategy based
on the combined reaction of tridentate pi-donor and monodentate
pi-acceptor ligands with the [M"N]2þ (M¼99mTc, 188Re) metallic
functional group. A version of this approach, which proved to be
particularly convenient for labeling short peptide sequences was
employed here. This involves designing of the appropriate triden-
tate chelating system through a simple combination of a pair of
natural aminoacids. The resulting Tc-99m and Re-188 radiophar-
maceuticals were demonstrated to possess the same molecular
geometry and, as a consequence, their observed biological beha-
vior was superimposable, thus providing a further example
of a true diagnostic and therapeutic (theranostic) Tc-99m/Re-188
matching pair.
Fig. 6. Time variation of radiochemical purity (RCP) of [99mTc][Tc(N)(Cys-Cys-SP)
(PCN)] after incubation with mouse (▲), rat (■) and human serum (●).
Fig. 7. Hybrid SPECT/CT image of a mouse collected after 60 min from adminis-
tration of 74 MBq of [99mTc][Tc(N)(Cys-Cys-SP)(PCN)].
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